Jean Jacques Bienaime Acquires 400 Shares of Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $237.47 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $14.81 billion, a PE ratio of 27.39 and a beta of 0.41. The company has a 50 day moving average price of $233.59 and a two-hundred day moving average price of $223.07. Ascendis Pharma A/S has a 12-month low of $158.16 and a 12-month high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. As a group, equities analysts predict that Ascendis Pharma A/S will post 11.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Evercore restated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup assumed coverage on shares of Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Morgan Stanley restated an “overweight” rating and issued a $256.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. Finally, Barclays boosted their price objective on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and an average target price of $295.39.

Hedge Funds Weigh In On Ascendis Pharma A/S

Large investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its holdings in Ascendis Pharma A/S by 2.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after buying an additional 130,000 shares during the period. Capital International Investors increased its holdings in Ascendis Pharma A/S by 0.4% in the 3rd quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock valued at $608,481,000 after buying an additional 13,685 shares during the period. Wellington Management Group LLP increased its holdings in Ascendis Pharma A/S by 95.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after buying an additional 880,836 shares during the period. Principal Financial Group Inc. increased its holdings in Ascendis Pharma A/S by 29.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after buying an additional 232,730 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter valued at $166,367,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.